|
|
Found results for
1.
|
Methods and kits for quantifying the removal of mock virus particles from a purified solution
| Application Number |
18212606 |
| Grant Number |
12553894 |
| Status |
In Force |
| Filing Date |
2023-06-21 |
| First Publication Date |
2024-03-14 |
| Grant Date |
2026-02-17 |
| Owner |
Cygnus Technologies, LLC (USA)
|
| Inventor |
|
Abstract
The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.
IPC Classes ?
- A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
- A61K 39/12 - Viral antigens
- G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- A61J 1/00 - Containers specially adapted for medical or pharmaceutical purposes
- A61K 39/00 - Medicinal preparations containing antigens or antibodies
- A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
- C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
|
2.
|
STOCK SOLUTION OF RETROVIRUS LIKE PARTICLES WITH METHOD AND KIT
| Application Number |
17167808 |
| Status |
Pending |
| Filing Date |
2021-02-04 |
| First Publication Date |
2021-05-27 |
| Owner |
CYGNUS TECHNOLOGIES, LLC (USA)
|
| Inventor |
|
Abstract
The present invention relates to a stock solution (RLP Stock Solution) of mammalian cell-endogenous retrovirus like particles (RLP), a method of preparing a RLP stock solution, a kit containing a RLP stock solution, and a method of quantifying the amount of RLP removed from a solution. An RLP stock solution will contain a high concentration of RLP and an extremely low amount of any therapeutic proteins of interest. In some instances, an RLP stock solution will contain a very low amount of natural mammalian host cell protein (HCP) and DNA. The method of preparing a RLP stock solution will consist of the production of RLP during fermentation or cell culturing and the subsequent purification of RLP from fermentation or cell culture solution. The kit will comprise at least two containers. One container comprised of RLP stock solution and one comprised of PCR primers or one or more antibodies. The method of quantifying RLP comprises the steps of adding RLP stock solution to an in-process solution containing a recombinant therapeutic of interest, processing the resulting solution through a bioprocess purification technique, and then quantifying the amount of RLP removed.
IPC Classes ?
- C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
- C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
- G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
|
3.
|
CYGNUS
| Serial Number |
90245534 |
| Status |
Registered |
| Filing Date |
2020-10-09 |
| Registration Date |
2021-03-30 |
| Owner |
CYGNUS TECHNOLOGIES, LLC (USA)
|
| NICE Classes ? |
42 - Scientific, technological and industrial services, research and design
|
Goods & Services
Scientific research and development in the field of identifying and analyzing protein impurities in biological drug manufacturing processes
|
4.
|
CYGNUS TECHNOLOGIES PART OF MARAVAI LIFESCIENCES
| Serial Number |
90235940 |
| Status |
Registered |
| Filing Date |
2020-10-05 |
| Registration Date |
2021-03-30 |
| Owner |
CYGNUS TECHNOLOGIES, LLC (USA)
|
| NICE Classes ? |
42 - Scientific, technological and industrial services, research and design
|
Goods & Services
Scientific research and development in the field of identifying and analyzing protein impurities in biological drug manufacturing processes
|
5.
|
Methods and kits for quantifying the removal of mock virus particles from a purified solution
| Application Number |
16386327 |
| Grant Number |
11754565 |
| Status |
In Force |
| Filing Date |
2019-04-17 |
| First Publication Date |
2019-11-21 |
| Grant Date |
2023-09-12 |
| Owner |
CYGNUS TECHNOLOGIES, LLC (USA)
|
| Inventor |
|
Abstract
The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.
IPC Classes ?
- G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
- A61K 39/12 - Viral antigens
- A61K 39/00 - Medicinal preparations containing antigens or antibodies
- A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
- C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
|
6.
|
Methods for evaluating viral clearance from a process solution employing mock viral particles
| Application Number |
15456487 |
| Grant Number |
10309963 |
| Status |
In Force |
| Filing Date |
2017-03-11 |
| First Publication Date |
2017-07-06 |
| Grant Date |
2019-06-04 |
| Owner |
CYGNUS TECHNOLOGIES, LLC (USA)
|
| Inventor |
|
Abstract
The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.
IPC Classes ?
- A61K 39/12 - Viral antigens
- G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
- A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
- C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
- A61K 39/00 - Medicinal preparations containing antigens or antibodies
|
7.
|
Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles
| Application Number |
14481364 |
| Grant Number |
09632087 |
| Status |
In Force |
| Filing Date |
2014-09-09 |
| First Publication Date |
2015-03-12 |
| Grant Date |
2017-04-25 |
| Owner |
CYGNUS TECHNOLOGIES, LLC (USA)
|
| Inventor |
|
Abstract
The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.
IPC Classes ?
- A61K 39/12 - Viral antigens
- G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
- A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
- A61K 39/00 - Medicinal preparations containing antigens or antibodies
|
|
